Naltrexone long-acting formulation in the treatment of alcohol dependence

References

• AlimTNTaiBChiangCNHarrisLSTolerability study of a depot form of naltrexone substance abusers [abstract]NIDA Res Monogr1995153253 Problems of Drug Dependence 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II
   Google Scholar
• Alkermes, IncVivitrol™ [package insert]2005Cambridge, MAAlkermes, Inc
   Google Scholar
• BartusRTEmerichDFHotzJVivitrex®, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in ratsNeuropsychopharmacology20032819738212931140
   PubMed Web of Science ®Google Scholar
• BlaakEGender differences in fat metabolismCurr Opin Clin Nutr Metab Care2001449950211706283
   PubMed Web of Science ®Google Scholar
• ComerSDCollinsEDKleberHDDepot naltrexone: long-lasting antagonism of the effects of heroin in humansPsychopharmacology20021593516011823887
   PubMed Web of Science ®Google Scholar
• ConigraveKMDegenhardtLJWhitfieldJBCDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative projectAlcohol Clin Exp Res200226332911923585
   PubMed Web of Science ®Google Scholar
• CroopRSFaulknerEBLabriolaDFThe safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study GroupArch Gen Psychiatry199754113059400350
   PubMed Web of Science ®Google Scholar
• FeinnRKranzlerHRDoes effect size in naltrexone trials for alcohol dependence differ for single-site vs multi-center studies?Alcohol Clin Exp Res200529983815976524
   PubMed Web of Science ®Google Scholar
• GallowayGPKochMCelloRPharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trialBMC Psychiatry200551815804355
   PubMed Web of Science ®Google Scholar
• GarbuttJCKranzlerHRO’MalleySSEfficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trialJAMA200529316172515811981
   PubMed Web of Science ®Google Scholar
• GiordanoALNockBCiceroTJAntagonist-induced up-regulation of the putative epsilon opioid receptor in rat brain: comparison with kappa, mu and delta opioid receptorsJ Pharmacol Exp Ther1990255536402173747
   PubMed Web of Science ®Google Scholar
• HeishmanSJFrancis-WoodAKeenanRMHarrisLSSafety and pharmacokinetics of a new formulation of naltrexone [abstract]NIDA Res Monogr199414182 Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Volume II
   Google Scholar
• JohnsonBAA synopsis of the pharmacological rationale, properties, and therapeutic effects of depot preparations of naltrexone for treating alcohol dependenceExpert Opin Pharmacother2006710657316722816
   PubMed Web of Science ®Google Scholar
• JohnsonBAAit-DaoudNNeuropharmacological treatments for alcoholism: scientific basis and clinical findingsPsychopharmacology20001493274410867960
   PubMed Web of Science ®Google Scholar
• JohnsonBAAit-DaoudNAubinH-JA pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependenceAlcohol Clin Exp Res20042813566115365306
   PubMed Web of Science ®Google Scholar
• JohnsonBAAit-DaoudNPrihodaTJCombining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidenceAlcohol Clin Exp Res2000247374210832917
   PubMed Web of Science ®Google Scholar
• JohnsonBAMannKWillenbringMLChallenges and opportunities for medications development in alcoholism: an international perspective on collaborations between academia and industryAlcohol Clin Exp Res20052915284016156050
   PubMed Web of Science ®Google Scholar
• KieferFJahnHTarnaskeTComparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled studyArch Gen Psychiatry20036092912511176
   PubMed Web of Science ®Google Scholar
• KieferFJahnHWiedemannKA neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatmentPharmacopsychiatry200538184616025425
   PubMed Web of Science ®Google Scholar
• KingACVolpicelliJRGunduzMNaltrexone biotransformation and incidence of subjective side effects: a preliminary studyAlcohol Clin Exp Res19972190699267542
   PubMed Web of Science ®Google Scholar
• KoobGFAlcoholism: allostasis and beyondAlcohol Clin Exp Res2003272324312605072
   PubMed Web of Science ®Google Scholar
• KranzlerHRModesto-LoweVNuwayserESSustained-release naltrexone for alcoholism treatment: a preliminary studyAlcohol Clin Exp Res199822107499726277
   PubMed Web of Science ®Google Scholar
• KranzlerHRWessonDRBillotLNaltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trialAlcohol Clin Exp Res2004281051915252291
   PubMed Web of Science ®Google Scholar
• LahtiRACollinsRJChronic naloxone results in prolonged increases in opiate binding sites in brainEur J Pharmacol1978511856212280
   PubMed Web of Science ®Google Scholar
• LaphamSScreening and brief intervention in the criminal justice systemAlcohol Res Health2004/200528859319006996
   PubMedGoogle Scholar
• LewisDHChasinMLangerRControlled release of bioactive agents from lactide/glycolide polymersBiodegradable polymers as drug delivery systems1990New YorkMarcel Dekker141
   Google Scholar
• McCaulMEWandGSRohdeCSerum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkersAlcohol Clin Exp Res20002413859111003204
   PubMed Web of Science ®Google Scholar
• MonterossoJRFlanneryBAPettinatiHMPredicting treatment response to naltrexone: the influence of craving and family historyAm J Addict2001102586811579624
   PubMed Web of Science ®Google Scholar
• O’MalleySSJaffeAJChangGNaltrexone and coping skills therapy for alcohol dependence: a controlled studyArch Gen Psychiatry19924988171444726
   PubMed Web of Science ®Google Scholar
• OslinDWBerrettiniWKranzlerHRA functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patientsNeuropsychopharmacology20032815465212813472
   PubMed Web of Science ®Google Scholar
• RohsenowDJColbySMMontiPMPredictors of compliance with naltrexone among alcoholicsAlcohol Clin Exp Res2000241542911045863
   PubMed Web of Science ®Google Scholar
• ShiveMSAndersonJMBiodegradation and biocompatibility of PLA and PLGA microspheresAdv Drug Deliv Rev19972852410837562
   PubMed Web of Science ®Google Scholar
• SpanagelRZieglgansbergerWAnti-craving compounds for ethanol: new pharmacological tools to study addictive processesTrends Pharmacol Sci1997185499090311
   PubMed Web of Science ®Google Scholar
• SrisurapanontMJarusuraisinNOpioid antagonists for alcohol dependenceCochrane Database Syst Rev20051CD00186715674887
   PubMedGoogle Scholar
• VolpicelliJRAltermanAIHayashidaMNaltrexone in the treatment of alcohol dependenceArch Gen Psychiatry199249876801345133
   PubMed Web of Science ®Google Scholar
• VolpicelliJRRhinesKCRhinesJSNaltrexone and alcohol dependence: role of subject complianceArch Gen Psychiatry199754737429283509
   PubMed Web of Science ®Google Scholar
• WeissFPorrinoLJBehavioral neurobiology of alcohol addiction: recent advances and challengesJ Neurosci2002223332711978808
   PubMed Web of Science ®Google Scholar
• WiseRABozarthMAA psychomotor stimulant theory of addictionPsychol Rev198794469923317472
   PubMed Web of Science ®Google Scholar
• ZukinRSSugarmanJRFitz-SyageMLNaltrexone-induced opiate receptor supersensitivityBrain Res1982245285926289965
   PubMed Web of Science ®Google Scholar